NCT04986748 Using QPOP to Predict Treatment for Sarcomas and Melanomas
| NCT ID | NCT04986748 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Cancer Centre, Singapore |
| Condition | Sarcoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2020-09-08 |
| Primary Completion | 2028-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2020-09-08 with a primary completion date of 2028-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multi-cohort proof of concept study involving patients with sarcomas or melanomas. Patient models, both two- and three-dimensional, will be derived from tumour samples. These will then be used to evaluate drug sensitivities ex vivo. Enrolled patients will undergo resections or biopsies as part of standard-of-care, which will be used to generate patient models. Patients will receive standard-of-care systemic treatment. Patient models will also be subjected up to a 14-drug screening panel. The majority of drugs in the respective drug panels has been shown to have activity in the respective cancers and would be used in the standard-of-care setting by treating physicians.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of sarcoma or melanoma * At least 1 tumour lesion amenable to fresh biopsy or resection * Signed informed consent from patient or legal representative * Able to comply with study-related procedures Exclusion Criteria: * There are no specific exclusion criteria if patients meet the inclusion criteria
Contact & Investigator
Valerie Shiwen Yang, BSc, MB BChir, PhD
PRINCIPAL INVESTIGATOR
National Cancer Centre, Singapore
Frequently Asked Questions
Who can join the NCT04986748 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 99 Years, studying Sarcoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04986748 currently recruiting?
Yes, NCT04986748 is actively recruiting participants. Contact the research team at valerie.yang.s.w@singhealth.com.sg for enrollment information.
Where is the NCT04986748 trial being conducted?
This trial is being conducted at Singapore, Singapore.
Who is sponsoring the NCT04986748 clinical trial?
NCT04986748 is sponsored by National Cancer Centre, Singapore. The principal investigator is Valerie Shiwen Yang, BSc, MB BChir, PhD at National Cancer Centre, Singapore. The trial plans to enroll 100 participants.